Legend Biotech Corporation (LEGN)
Nasdaq: LEGN · Pharmaceutical Preparations · Somerset, NJ · filing with the SEC since 2020
Who owns Legend Biotech Corporation
As filed with the SECHolders of 5% or more
1
Fmr LLC holds 15% of COMMON STOCK, as its SCHEDULE 13G/A filed Aug 6, 2026 says.
Directors and officers
14
report now, of 14 people on the record since 2026. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Fmr LLC
SCHEDULE 13G/A · filed Aug 6, 2026 · COMMON STOCK · 13.1% in Feb 5, 2026
T. Rowe Price Associates, Inc.
SCHEDULE 13G/A · filed Feb 14, 2025 · ADR · reported falling below 5%
What LEGN reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Hainan Chuanji Biotechnology Co Ltd
An entity · subsidiary · owns, named in the 20-F filed Mar 10, 2026
Legend Biotech Belgium B V
An entity · subsidiary · owns, named in the 20-F filed Mar 10, 2026
Legend Biotech H K Limited
An entity · subsidiary · owns, named in the 20-F filed Mar 10, 2026
Legend Biotech Ireland Limited
An entity · subsidiary · owns, named in the 20-F filed Mar 10, 2026
Legend Biotech Limited
An entity · subsidiary · owns, named in the 20-F filed Mar 10, 2026
Nanjing Legend Biotechnology Co Ltd
An entity · subsidiary · owns, named in the 20-F filed Mar 10, 2026
Shanghai Chuanji Biotech Co Ltd
An entity · subsidiary · owns, named in the 20-F filed Mar 10, 2026
7 subsidiaries in 5 countries, from the list filed with the 20-F filed Mar 10, 2026.
Insider tradesForm 4
5sales
0purchases
0sales on a scheduled plan
4people selling
$600,000sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 1, 2025 to Oct 1, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 1, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window4 of 14 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Sanders Corazon (Corsee) D. | director | 1 | $300,000 | 0 | 0 | $0 |
| Huang Ying | Chief Executive Officer | 2 | $200,000 | 0 | 0 | $0 |
| Casey Patrick John | director | 1 | $100,000 | 0 | 0 | $0 |
| Santos Carlos E | Chief Financial Officer | 1 | $0 | 0 | 0 | $0 |